Treatment completion rates of olanzapine and risperidone in long acting injectable formulations for the treatment of schizophrenia: A comparison of single arm open-label studies

被引：0
|
作者：
Ascher-Svanum, H. [1 ]
Montgomery, W. [1 ]
Brnabic, A. [2 ]
Lawson, A. [1 ]
Tomori, O. [1 ]
Coleman, K. [3 ]
Lynch, L. [3 ]
Chen, P. [4 ]
Andersen, S. W. [1 ]
McDonnell, D. P. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, N Ryde, NSW, Australia
[3] Hlth Technol Analysts, Balmain, NSW, Australia
[4] Eli Lilly & Co, Singapore, Singapore
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：161 / 162
页数：2
相关论文
共 50 条
  • [41] Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity
    Rubio, Gabriel
    Martinez, Isabel
    Ponce, Guillermo
    Jimenez-Arriero, Miguel Angel
    Lopez-Munoz, Francisco
    Alamo, Cecilio
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (08): : 531 - 539
  • [42] Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients
    Verma, Swapna
    Subramaniam, Mythily
    Abdin, Edimansyah
    Sim, Kang
    Su, Alex
    Lee, Nelson
    Chong, Siow Ann
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2010, 25 (03) : 230 - 235
  • [43] Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
    Gaebel, Wolfgang
    Schreiner, Andreas
    Bergmans, Paul
    de Arce, Rosario
    Rouillon, Frederic
    Cordes, Joachim
    Eriksson, Lars
    Smeraldi, Enrico
    NEUROPSYCHOPHARMACOLOGY, 2010, 35 (12) : 2367 - 2377
  • [44] Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
    Wolfgang Gaebel
    Andreas Schreiner
    Paul Bergmans
    Rosario de Arce
    Frédéric Rouillon
    Joachim Cordes
    Lars Eriksson
    Enrico Smeraldi
    Neuropsychopharmacology, 2010, 35 : 2367 - 2377
  • [45] Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study
    Detke, H.
    Weiden, P. J.
    Lambert, T.
    Llorca, P. M.
    Choukour, M.
    Watson, S. B.
    Brunner, E.
    Ascher-Svanum, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S464 - S464
  • [46] A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia
    Perez, Victor
    Canas, Fernando
    Tafalla, Monica
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (03) : 138 - 149
  • [47] Comparison of long-acting injectable risperidone and oral novel antipsychotic drugs for treatment in early phase of schizophrenia spectrum psychosis
    Malla, A
    Binder, C
    Chue, P
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 38S - 39S
  • [48] A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial
    D. V. Jeste
    Mark Klausner
    Martin Brecher
    Christopher Clyde
    Robert Jones
    Psychopharmacology, 1997, 131 : 239 - 247
  • [49] Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial
    Kim, Sung-Wan
    Shin, Il-Seon
    Kim, Jae-Min
    Lee, Seung-Hyun
    Lee, Jeong-Hoon
    Yoon, Bo-Hyun
    Yang, Su-Jin
    Hwang, Michael Y.
    Yoon, Jin-Sang
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (07): : 1504 - 1509
  • [50] A clinical evaluation of risperidone in the treatment of schizophrenia: A 10-week, open-label, multicenter trial
    Jeste, DV
    Klausner, M
    Brecher, M
    Clyde, C
    Jones, R
    Abuzzahab, FS
    Ahmad, A
    Ahmed, S
    Ainslie, G
    Alidon, G
    Jampala, VC
    Andriulli, G
    Ashleigh, EA
    Aukstuolis, J
    Bacon, RJ
    Badhiwala, SP
    Bagri, KS
    Baldwin, JD
    Bardinelli, AJ
    Baron, D
    Bartholow, G
    Beach, RL
    Bera, RB
    Berkey, R
    Bird, LJ
    Boyer, W
    Escalona, R
    Caccioppoli, G
    Taliaferro, J
    Carter, RG
    Centric, RW
    Charalampous, KD
    Chastek, JW
    Chauhan, N
    Cho, SN
    Cohen, AJ
    Cohn, CK
    Corder, SL
    Cuervo, MS
    Cutler, MO
    Damera, BR
    Hamilton, RS
    Daniels, K
    Daskalov, Z
    David, A
    Davis, H
    deLeon, J
    Dellario, AV
    Dirksen, JS
    DosSantos, E
    PSYCHOPHARMACOLOGY, 1997, 131 (03) : 239 - 247
12345